Does the impact of Markman orders vary by technology complexity?
Some patent litigators observe that patent disputes involving less complicated technologies tend to settle faster after claim construction. What does Docket Navigator data say?
Some patent litigators observe that patent disputes involving less complicated technologies tend to settle faster after claim construction. What does Docket Navigator data say?
Here’s the critical background to know as innovators today participate in a USPTO listening session about the intersection between standards development and IP
Despite unusual circumstances of the fingolimod disputes, the cases highlight some of the potential pitfalls facing pharma patentees in Germany and elsewhere in Europe
14 August 2023
Its evolution and the related implications are critical for both originators and generics
09 August 2023
The new court is being used far more by local companies than by innovators from other parts of the world
07 August 2023
AstraZeneca is the third Big Pharma company to pay BMS a nine-figure sum for the use of its immuno-oncology patents
04 August 2023
Rare decision in a BPCIA dispute gives a tactical advantage to biosimilar producers
01 August 2023
US appellate court confirms IRS may no longer deny generic drugmakers the ability to deduct ANDA litigation costs
31 July 2023
The company’s distinctive dealmaking approach has produced many successes to date
28 July 2023
Head of IP Nick Finnie speaks to IAM about the importance of visibility when working for a smaller company competing in a global market
21 July 2023
Case concerns 20 asserted patents but this figure may be whittled down during litigation process
21 July 2023
SNIPR Biome has five patents revived but more disputes are on the horizon
18 July 2023
Unlock unlimited access to all IAM content